FDA
-
-
-
-
-
-
-
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)
-
-
-
-
-
-
-
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
-
-
-
-
-
-
-
Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

